Results 1 to 10 of about 286,222 (357)

Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies

Cell Reports, 2021
Summary: An effective HIV-1 vaccine will likely need to elicit broadly neutralizing antibodies (bNAbs). Broad and potent VRC01-class bNAbs have been isolated from multiple infected individuals, suggesting that they could be reproducibly elicited by ...
Emilie Seydoux, Yu-Hsin Wan, Junli Feng, Abigail Wall, Safia Aljedani, Leah J. Homad, Anna J. MacCamy, Connor Weidle, Matthew D. Gray, Lauren Brumage, Justin J. Taylor, Marie Pancera, Leonidas Stamatatos, Andrew T. McGuire   +13 more
doaj   +1 more source

Blood microbiota diversity determines response of advanced colorectal cancer to chemotherapy combined with adoptive T cell immunotherapy

OncoImmunology, 2021
Human microbiota influence the response of malignancies to treatment with immune checkpoint blockade; however, their impact on other forms of immunotherapy is poorly understood.
Duo Yang, Xiaoli Wang, Xinna Zhou, Jing Zhao, Huabing Yang, Shuo Wang, Michael A. Morse, Jiangping Wu, Yanhua Yuan, Sha Li, Amy Hobeika, Herbert Kim Lyerly, Jun Ren   +12 more
doaj   +1 more source

Hijacking Host Immunity by the Human T-Cell Leukemia Virus Type-1: Implications for Therapeutic and Preventive Vaccines

Viruses, 2022
Human T-cell Leukemia virus type-1 (HTLV-1) causes adult T-cell leukemia/lymphoma (ATLL), HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and other inflammatory diseases.
Cynthia A. Pise-Masison, Genoveffa Franchini   +1 more
doaj   +1 more source

HIV vaccine candidate efficacy in female macaques mediated by cAMP-dependent efferocytosis and V2-specific ADCC

Nature Communications, 2023
HIV vaccine development can be aided by knowledge of correlates of protection. Here the authors identify engagement and reprogramming of tolerogenic CD14+ myeloid cells mediating a spatiotemporal balance of pro- and anti-inflammatory responses, as ...
Massimiliano Bissa, Sohyoung Kim, Veronica Galli, Slim Fourati, Sarkis Sarkis, Anush Arakelyan, Isabela Silva de Castro, Mohammad Arif Rahman, Saori Fujiwara, Monica Vaccari, Jeffrey A. Tomalka, James D. Stamos, Luca Schifanella, Giacomo Gorini, Ramona Moles, Anna Gutowska, Guido Ferrari, Alexei Lobanov, David C. Montefiori, George W. Nelson, Margaret C. Cam, Marita Chakhtoura, Elias K. Haddad, Melvin N. Doster, Katherine McKinnon, Sophia Brown, David J. Venzon, Hyoyoung Choo-Wosoba, Matthew W. Breed, Kristin E. Killoran, Joshua Kramer, Leonid Margolis, Rafick P. Sekaly, Gordon L. Hager, Genoveffa Franchini   +34 more
doaj   +1 more source

Antigen-Specific Polyclonal Cytotoxic T Lymphocytes Induced by Fusions of Dendritic Cells and Tumor Cells [PDF]

, 2010
The aim of cancer vaccines is induction of tumor-specific cytotoxic T lymphocytes (CTLs) that can reduce the tumor mass. Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune ...
Gong, Jianlin, Hara, Eiichi, Homma, Sadamu, Koido, Shigeo, Namiki, Yoshihisa, Ohkusa, Toshifumi, Tajiri, Hisao   +6 more
core   +11 more sources

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation

Nature Communications, 2020
Currently there is neither a vaccine nor an effective treatment strategy available for COVID19. Here, Hurlburt et al. provide the crystal structure of a patient-derived monoclonal antibody neutralizing SARS-CoV-2 via shedding of the S1 subunit and ...
Nicholas K. Hurlburt, Emilie Seydoux, Yu-Hsin Wan, Venkata Viswanadh Edara, Andrew B. Stuart, Junli Feng, Mehul S. Suthar, Andrew T. McGuire, Leonidas Stamatatos, Marie Pancera   +9 more
doaj   +1 more source

The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant [PDF]

, 2013
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a potent type I interferon (IFN) inducer, was evaluated as a chemotherapeutic agent in mouse cancer models and proved to be well tolerated in human cancer clinical trials.
Akira, S, Aoshi, T, Coban, C, Dessailly, BH, Ishii, KJ, Ito, J, Jounai, N, Kobiyama, K, Kuroda, E, Mizuguchi, K, Ohata, K, Tang, CK   +11 more
core   +8 more sources

Cervical Cancer-Associated Human Papillomavirus 16 E7 Oncoprotein Inhibits Induction of Anti-Cancer Immunity by a CD4+ T Cell Dependent Mechanism [PDF]

, 2009
Attempts to develop therapeutic vaccines against cervical cancer have been proven difficult. One of the major causes of the failure is due to the use of the wrong mouse models based on transplantable tumours in testing the efficacy of vaccines.
Germain J. Fernando, Jie Zhong, Marion E. G. Brunck, Xiao Song Liu   +3 more
core   +2 more sources

Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems [PDF]

, 2014
Cervical cancer is the second-most-common cause of malignancies in women worldwide, and the oncogenic activity of the human papilloma virus types (HPV) E7 protein has a crucial role in anogenital tumors.
Atyabi, F., Ghaemi, A., Gorji, A., Kalhor, H.R., Kelishadi, M., Moradi, A., Sajadian, A., Tabarraei, A., Tahamtan, A.   +8 more
core   +3 more sources

In Vivo Treatment with Insulin-like Growth Factor 1 Reduces CCR5 Expression on Vaccine-Induced Activated CD4⁺ T-Cells

Vaccines, 2023
At the heart of the DNA/ALVAC/gp120/alum vaccine’s efficacy in the absence of neutralizing antibodies is a delicate balance of pro- and anti-inflammatory immune responses that effectively decreases the risk of SIVmac251 acquisition in macaques.
Massimiliano Bissa, Veronica Galli, Luca Schifanella, Monica Vaccari, Mohammad Arif Rahman, Giacomo Gorini, Nicolò Binello, Sarkis Sarkis, Anna Gutowska, Isabela Silva de Castro, Melvin N. Doster, Ramona Moles, Guido Ferrari, Xiaoying Shen, Georgia D. Tomaras, David C. Montefiori, Kombo F. N’guessan, Dominic Paquin-Proulx, Pamela A. Kozlowski, David J. Venzon, Hyoyoung Choo-Wosoba, Matthew W. Breed, Joshua Kramer, Genoveffa Franchini   +23 more
doaj   +1 more source